

August 10, 2018

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001
Scrip code: 512529

The National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (E),
Mumbai - 400 051
Scrip code: SEQUENT

Dear Sir/ Madam,

Subject: Unaudited financial results for the quarter ended June 30, 2018 (Revised)

This is with reference to the intimation submitted by the Company on the captioned subject on August 9, 2018, kindly note that on account of typographical issue, we are submitting herewith revised Unaudited Financial Results (Standalone & Consolidated) for the quarter ended June 30, 2018.

The change is on account of the following:

“Point No 7 under Notes to the Statement of Consolidated Unaudited Financial Results for the Quarter ended June 30, 2018:

- Revenue from operation was erroneously mentioned as INR 128.30 Lakhs instead of INR 1283.01 Lakhs.
- The amount of Loss After Tax relating to Bremer was erroneously mentioned as INR 4.53 Lakhs instead of INR 45.29 Lakhs.”

You are requested to take the same on record.

Thanking you,

Yours faithfully,
For Sequent Scientific Limited


Krupesh Mehta
Company Secretary

Encl: A/a

SeQuent Scientific Limited

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF SEQUENT SCIENTIFIC LIMITED

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **SEQUENT SCIENTIFIC LIMITED** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the quarter ended June 30, 2018 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.

This Statement, which is the responsibility of the Parent's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Parent's personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.

3. The Statement includes the results of the following entities:

- i) Alivira Animal Health Australia Pty Ltd;
- ii) Alivira Animal Health Limited, Ireland;
- iii) Alivira Animal Health Limited, India;
- iv) Alivira Saude Animal Brasil Participacoes Ltda;
- v) Alivira UA Limited;
- vi) Alivira France
- vii) Bremer Pharma GMBH;
- viii) Comercial Vila Veterinaria de Lleida S.L;
- ix) Elysian Life Sciences Private Limited;
- x) Fendigo BV;
- xi) Fendigo SA;
- xii) Interchange Veterinária Indústria E Comércio Ltda;
- xiii) Laboratorios Karizoo, S.A;
- xiv) Laboratorios Karizoo, S.A. De C.V. (Mexico);
- xv) N-Vet AB;
- xvi) Phytotherapeutic Solutions S.L;
- xvii) Provet Veteriner Urunleri Sanayi ve Ticaret A.S;
- xviii) SeQuent Antibiotics Private Limited;

WJ

Deloitte Haskins & Sells

- xix) SeQuent Pharmaceuticals Private Limited;
- xx) SeQuent Research Limited;
- xxi) Topkim-Topkapi Ilac Premiks San. ve Tic. A.S;
- xxii) Vila Viña Participacions S.L ;

4. Based on our review conducted as stated above and based on the consideration of the review reports of other auditors referred to in paragraph 5 below, and except for the possible effects of the matters described in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. We did not review the interim financial results of twelve subsidiaries included in the consolidated unaudited financial results, whose interim financial results reflect total revenues of Rs.16,443.46 lakhs for the quarter ended June 30, 2018, and total profit after tax of Rs.534.79 lakhs and total comprehensive income of Rs.534.79 lakhs for the quarter ended June 30, 2018, as considered in the consolidated unaudited financial results.

These interim financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our report on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors.

Our report on the Statement is not modified in respect of these matters.

6. The consolidated unaudited financial results includes the interim financial results of nine subsidiaries which have not been reviewed by their auditors, whose interim financial results reflect total revenue Rs.434.72 lakhs for the quarter ended June 30, 2018, and total loss after tax of Rs.806.15 lakhs and total comprehensive loss of Rs.802.15 lakhs for the quarter ended June 30, 2018, as considered in the consolidated unaudited financial results.

For **DELOITTE HASKINS & SELLS**
Chartered Accountants
(Firm's Registration No. 008072S)



Sathya P. Koushik
Partner
(Membership No. 206920)


Mumbai, August 9, 2018
SPK/JKS/2018

SEQUENT SCIENTIFIC LIMITED

STATEMENT OF CONSOLIDATED UNAUDITED RESULTS FOR THE QUARTER ENDED 30 JUNE 2018

(Rs. in Lakhs)

Particulars	3 months ended 30-Jun-2018	Preceding 3 months ended 31-Mar-2018	Corresponding 3 months ended in the previous year 30-Jun-2017	Previous year ended 31-Mar-2018
	UNAUDITED	AUDITED (Refer note 11)	UNAUDITED	AUDITED
I Revenue from operations (Refer note 5)	23,515.20	23,275.86	19,423.20	84,944.80
II Other income	181.40	291.86	362.30	1,658.10
III Total Income (I+II)	23,696.60	23,567.72	19,785.50	86,602.90
IV Expenses				
(a).Cost of materials consumed	10,507.60	10,706.92	7,948.12	34,459.40
(b).Purchase of stock-in-trade	3,354.70	3,231.42	3,485.56	14,184.10
(c).Changes in inventories of finished goods, work-in-progress and stock-in-trade	(1,211.20)	(1,590.06)	(825.00)	(2,394.30)
(d).Excise duty on sale of goods	-	-	161.02	161.02
(e).Employee benefits expense	3,513.60	2,893.77	2,681.59	11,382.80
(f). Finance costs	778.30	967.56	610.37	3,306.90
(g).Depreciation and amortisation expense	963.80	948.07	1,008.31	4,134.30
(h).Other expense	5,098.90	5,008.87	4,464.46	18,853.80
Total expenses	23,005.70	22,166.55	19,534.43	84,088.02
V Profit/(loss) from continuing operations before tax and exceptional items (III-IV)	690.90	1,401.17	251.07	2,514.88
VI Exceptional items loss/ (gain) (net) (Refer note 6)	-	150.40	-	150.40
VII Profit/(loss) from continuing operations before tax (V-VI)	690.90	1,250.77	251.07	2,364.48
VIII Tax expense				
(a).Current tax	340.70	52.93	223.30	1,196.80
(b). MAT credit entitlement	(84.80)	(3.90)	-	(3.90)
(c) MAT credit entitlement written off	-	286.70	-	286.70
(d).Deferred tax	(13.00)	71.80	(30.70)	(133.90)
Total tax expenses (VIII)	242.90	407.53	192.60	1,345.70
IX Profit/(loss) from continuing operations after tax (VII-VIII)	448.00	843.24	58.47	1,018.78
X Profit/(loss) from discontinued operations	-	-	166.23	1,054.70
Gain on disposal of assets/settlement of liabilities attributable to the discontinued operations	-	39,264.00	-	41,009.50
Tax expense of discontinued operation				
(a).Current tax	-	-	-	362.73
(b). MAT credit entitlement	-	(362.73)	-	(362.73)
Profit/(loss) from discontinued operations after tax (Refer note 4)	-	39,626.73	166.23	42,064.20
XI Profit/(loss) for the period (IX+X)	448.00	40,469.97	224.70	43,082.98
XII Other comprehensive income				
Items that will not be reclassified to profit or loss				
(a).Re-measurement gain/(loss) on defined benefits plans	(5.00)	92.41	(3.60)	82.50
(b).Fair value gain / (loss) from investment in equity instruments	(7,711.90)	(5,099.01)	(3,230.80)	(14,195.41)
Items that may be reclassified to profit or loss				
(a).Exchange differences on translation of foreign operations	(136.56)	162.16	(66.10)	244.66
(b).Exchange differences on net investment in foreign operations	355.51	288.54	98.80	(3.61)
Total other comprehensive income	(7,497.95)	(4,555.90)	(3,201.70)	(13,871.86)
XIII Total comprehensive income for the period (XI+XII)	(7,049.95)	35,914.07	(2,977.00)	29,211.12
Profit for the period attributable to:				
- Owners of the Company	328.00	39,954.87	223.70	42,156.58
- Non-controlling interests	120.00	515.10	1.00	926.40
Other comprehensive income for the period attributable to:				
- Owners of the Company	(7,433.45)	(4,588.50)	(3,269.00)	(13,954.86)
- Non-controlling interests	(64.50)	32.60	67.30	83.00
Total comprehensive income for the period attributable to:				
- Owners of the Company	(7,105.45)	35,366.37	(3,045.30)	28,201.72
- Non-controlling interests	55.50	547.70	68.30	1,009.40
Earnings per equity share: (face value of Rs. 2 each) (not annualised)				
- for continuing operations				
(1) Basic (in Rs.)	0.14	0.14	(0.13)	(0.11)
(2) Diluted (in Rs.)	0.13	0.13	(0.13)	(0.11)
- for discontinued operations				
(1) Basic (in Rs.)	-	16.36	0.22	17.51
(2) Diluted (in Rs.)	-	16.25	0.22	17.40
- for continuing and discontinued operations				
(1) Basic (in Rs.)	0.14	16.50	0.09	17.40
(2) Diluted (in Rs.)	0.13	16.38	0.09	17.29
See accompanying notes to the financial results				



W

SEQUENT SCIENTIFIC LIMITED

Notes:

1. The unaudited financial results have been reviewed by the Audit Committee and taken on record by the Board of Directors at its meeting held on 9 August 2018.
2. The Company has only one reportable segment viz. Pharmaceuticals. Accordingly, no separate disclosure of segment information has been made.

3. Information on Standalone Results:

(Rs in Lakhs)

Particulars	3 months ended 30-Jun-2018	Preceding 3 months ended 31-Mar-2018	Corresponding 3 months ended in the previous year 30-Jun-2017	Previous year ended 31-Mar-2018
	UNAUDITED	AUDITED (Refer note 11)	UNAUDITED	AUDITED
Revenue from continuing operations	2,628.50	2,679.50	2,728.20	10,723.60
Profit/ (Loss) before tax from continuing operations	261.90	(170.40)	(273.50)	66.30
Profit/ (Loss) after tax from continuing operations	261.90	(404.92)	(273.50)	(220.37)
Profit/ (Loss) after tax from discontinued operations	-	39,516.43	826.70	40,861.10
Total comprehensive income	(7,459.00)	33,978.45	(2,675.70)	26,408.03

4a. Pursuant to the Scheme of Arrangement (the 'Scheme'), duly sanctioned by the National Company Law Tribunal (NCLT), Mumbai, vide Order dated 09 March 2018 ('Order'), with effect from the Appointment Date i.e. 01 October 2017, the Human API business of the Company was transferred to Solara Active Pharma Sciences Limited ('Solara').

Pursuant to the above, Sequent Penems Private Limited has ceased to be the subsidiary of the Company.

In line with the approved Scheme, the comparative information in these results for the quarter ended 30 June 2017 have been revised from the published financial results for that quarter to exclude the results of Human API business and Sequent Penems Private Limited which had revenue of Rs. 8,470.00 lakhs and expenses of Rs. 7,650.51 lakhs.

4b. During the previous year ended 31 March 2018, the Company completed the divestment of woman healthcare business (discontinued operations).

The results relating to discontinued business are as follows:

(Rs in Lakhs)

Particulars	Preceding 3 months ended 31-Mar-2018	Corresponding 3 months ended in the previous year 30-Jun-2017	Previous year ended 31-Mar-2018
	AUDITED (Refer note 11)	UNAUDITED	AUDITED
Total income	-	10,225.92	18,575.74
Total expenses	-	10,059.69	17,821.04
Profit/ (Loss) before exceptional items and tax	-	166.23	1,054.70
Exceptional items	-	-	-
Profit/ (Loss) before tax	-	166.23	1,054.70
Gain on disposal of assets/settlement of liabilities attributable to the discontinuing operations	39,264.00	-	41,009.50
Tax Expense of discontinued operations	(362.73)	-	-
Profit/ (Loss) for the period	39,626.73	166.23	42,064.20

5. Post implementation of Goods and Services Tax (GST) with effect from 01 July 2017, revenue from operations is disclosed net of GST. Revenue from operations for the earlier period included excise duty which is now subsumed in GST. Revenue from operations for the year ended 31 March 2018 included excise duty up to 30 June 2017. Accordingly, revenue from operations for the quarter ended 30 June 2018 are not comparable with those of the previous periods presented.

6. Exceptional items:

(Rs in Lakhs)

Particulars	Preceding 3 months ended 31-Mar-2018	Previous year ended 31-Mar-2018
	AUDITED (Refer note 11)	AUDITED
- Write off of ineligible GST credits	116.10	116.10
- Goodwill impairment	790.00	790.00
- Contingent consideration reversal	(931.26)	(931.26)
- liability towards pre-acquisition employee claims	175.56	175.56
Total	150.40	150.40

7. With effect from 01 April 2018, the Company, through its step down subsidiary Alivira Animal Health Limited, Ireland, has acquired 100% stake in Bremer Pharma GmbH (Bremer). The Company is in process of completing the Purchase Price Allocations of this acquisition and the business combination has been accounted for based on provisional amounts as permitted under the Indian Accounting Standard 103 "Business Combinations". The results for the quarter ended 30 June 2018 includes Revenue from operations Rs. 1,263.01 lakhs and Loss after tax Rs. 45.29 lakhs relating to Bremer.

8. During the quarter, the Company has revised the useful life of certain acquired intangible assets from 5 years to 20 years. Had the useful life been 5 years, the profit for the quarter ended 30 June 2018 would have reduced by Rs. 167.55 lakhs (net of deferred tax Rs. 54.09 lakhs).

9. 'Ind AS 115 - Revenue from Contract with Customers', mandatory for reporting periods beginning on or after 01 April 2018, replaces existing revenue recognition requirement. Under the modified retrospective approach, there were no significant adjustments required to the retained earnings as at 01 April 2018. Also, the application of Ind AS 115 did not have any significant impact on recognition and measurement of revenue and related items in the financial results of the Company.

10. The Company has assessed the impact of amendment to Appendix B to 'Ind AS 21- The Effects of Changes in Foreign Exchange Rates', effective from 01 April 2018, in respect of advances received / paid in foreign currency, and noted no material impact.

11. The above results includes the results for the quarter ended 31 March 2018, being the balancing figure between audited figures in respect of the full financial year and the recast published year to date figures up to the third quarter of the previous financial year.

12. The previous period figures have been regrouped wherever necessary to correspond with the current period disclosure.

For Sequent Scientific Limited

Manish Gupta

Manish Gupta
Managing Director



Place : Mumbai
Date : 9 August 2018

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS


TO THE BOARD OF DIRECTORS OF SEQUENT SCIENTIFIC LIMITED

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **SEQUENT SCIENTIFIC LIMITED** ("the Company"), for the quarter ended June 30, 2018 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **DELOITTE HASKINS & SELLS**
Chartered Accountants
(Firm's Registration No. 008072S)



Sathya P. Koushik
Partner

Membership No. 206920)

Mumbai, August 09, 2018
SPK/JKS/2018

STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER ENDED 30 JUNE 2018

(Rs. in Lakhs)

	Particulars	3 months ended	Preceding 3 months ended	Corresponding 3 months ended in previous year	Previous year ended
		30-Jun-2018	31-Mar-2018	30-Jun-2017	31-Mar-2018
		Unaudited	Audited (Refer note 10)	Unaudited	Audited
I	Revenue from operations (Refer note 3)	2,628.50	2,679.50	2,728.20	10,723.60
II	Other income	435.60	509.40	443.90	2,426.90
III	Total income (I+II)	3,064.10	3,188.90	3,172.10	13,150.50
IV	Expenses				
	(a) Cost of materials consumed	916.10	1,102.20	581.00	3,065.70
	(b) Purchases of stock-in-trade	1,026.60	948.10	1,262.00	4,914.30
	(c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	(160.80)	(35.10)	0.30	(42.20)
	(d) Excise duty on sale of goods	-	-	122.90	122.90
	(e) Conversion and processing charges	398.00	417.88	238.20	1,175.60
	(f) Employee benefits expense	157.50	182.50	363.60	1,185.00
	(g) Finance costs	1.30	8.10	17.50	39.20
	(h) Depreciation and amortisation expense	87.70	114.40	75.50	366.70
	(i) Other expenses	375.80	505.12	784.60	2,140.90
	Total expenses (IV)	2,802.20	3,243.20	3,445.60	12,968.10
V	Profit/(loss) from continuing operations before tax and exceptional items (III-IV)	261.90	(54.30)	(273.50)	182.40
VI	Exceptional items (gain) / loss (Refer note 7)	-	116.10	-	116.10
VII	Profit/(loss) from continuing operations before tax (V-VI)	261.90	(170.40)	(273.50)	66.30
VIII	Tax expense				
	(a) Current tax	55.60	(48.28)	-	3.87
	(b) MAT credit entitlement	(55.60)	(3.87)	-	(3.87)
	(c) MAT credit entitlement written off	-	286.67	-	286.67
	Total tax expenses (VIII)	-	234.52	-	286.67
IX	Profit/(loss) from continuing operations after tax (VII-VIII)	261.90	(404.92)	(273.50)	(220.37)
X	Profit/(loss) from discontinued operations	-	-	826.70	1,707.40
	Gain on demerger of Human API business	-	39,153.70	-	39,153.70
	Tax expense of discontinued operations				
	(a) Current tax	-	-	-	362.73
	(b) MAT credit entitlement	-	(362.73)	-	(362.73)
	Profit/(loss) from discontinued operations after tax (X) (Refer note 9)	-	39,516.43	826.70	40,861.10
XI	Profit/(loss) for the period (IX+X)	261.90	39,111.51	553.20	40,640.73
XII	Other comprehensive income				
	Items that will not be reclassified to profit or loss				
	(a) Re-measurements of defined benefits plans	(9.00)	(34.06)	1.90	(37.30)
	(b) Fair value gain / (loss) from investment in equity instruments (net)	(7,711.90)	(5,099.00)	(3,230.80)	(14,195.40)
	Total other comprehensive income for the period (XII)	(7,720.90)	(5,133.06)	(3,228.90)	(14,232.70)
XIII	Total comprehensive income for the period (XI+XII)	(7,459.00)	33,978.45	(2,675.70)	26,408.03
XIV	Earnings per equity share: (Face value of Rs. 2 each) (not-annualised)				
	- for continuing operations				
	(1) Basic (in Rs.)	0.11	(0.17)	(0.11)	(0.09)
	(2) Diluted (in Rs.)	0.11	(0.17)	(0.11)	(0.09)
	- for discontinued operations				
	(1) Basic (in Rs.)	-	16.31	0.34	16.86
	(2) Diluted (in Rs.)	-	16.20	0.34	16.75
	- for continuing and discontinued operations				
	(1) Basic (in Rs.)	0.11	16.14	0.23	16.77
	(2) Diluted (in Rs.)	0.11	16.03	0.23	16.66
	See accompanying notes to financial results				

W,



Notes:

- 1 The unaudited financial results have been reviewed by the Audit Committee and taken on record by the Board of Directors at its meeting held on 09 August 2018.
- 2 The Company has only one reportable segment viz. Pharmaceuticals. Accordingly, no separate disclosure of segment information has been made.
- 3 Post implementation of Goods and Services Tax (GST) with effect from 01 July 2017, revenue from operations is disclosed net of GST. Revenue from operations for the earlier period included excise duty which is now subsumed in GST. Revenue from operations for the year ended 31 March 2018 included excise duty upto 30 June 2017. Accordingly, revenue from operations for the quarter ended 30 June 2018 are not comparable with those of the previous periods presented.
- 4 During the quarter, the Company, through its step down subsidiary Alivira Animal Health Limited, Ireland, has acquired 100% stake in Bremer Pharma GMBH.
- 5 'Ind AS 115- Revenue from Contract with Customers', mandatory for reporting periods beginning on or after 01 April 2018, replaces existing revenue recognition requirement. Under the modified retrospective approach, there were no significant adjustments required to the retained earnings as at 01 April 2018. Also, the application of Ind AS 115 did not have any significant impact on recognition and measurement of revenue and related items in the financial results of the Company.
- 6 The Company has assessed the impact of amendment to Appendix B to 'Ind AS 21- The Effects of Changes in Foreign Exchange Rates', effective from 01 April 2018, in respect of advances received / paid in foreign currency, and noted no material impact.
- 7 Exceptional items for the quarter and year ended 31 March 2018 comprises write-off of ineligible GST credits.
- 8 Tax expenses has been accrued during the current quarter based on estimated Minimum Alternate Tax applicable to the entity and for previous periods, tax expenses are split between continuing and discontinued operations based on book profits from the respective operations.
- 9 Pursuant to the Scheme of Arrangement (the 'Scheme'), duly sanctioned by the National Company Law Tribunal (NCLT), Mumbai, vide Order dated 09 March 2018, with effect from the Appointment Date i.e. 01 October 2017, the Human API business of the Company was transferred to Solara Active Pharma Sciences Limited. In line with the approved Scheme, the comparative information in these results for the quarter ended 30 June 2017 have been revised from the published financial results for that quarter to exclude the result of the Human API business which had a revenue of Rs. 8,461.60 lakhs and expenses of Rs. 7,634.90 lakhs.

(Rs. in Lakhs)

Particulars	Preceding 3 months ended 31-Mar-2018	Corresponding 3 months ended in previous year 30-Jun-2017	Previous year ended 31-Mar-2018
	Audited (Refer note 10)	Unaudited	Audited
Total income	-	8,461.60	16,795.60
Total expenses	-	7,634.90	15,088.20
Profit/(loss) before exceptional items and tax	-	826.70	1,707.40
Exceptional items	-	-	-
Profit/(loss) before tax	-	826.70	1,707.40
Gain on demerger of Human API business	39,153.70	-	39,153.70
Tax expense	(362.73)	-	-
Profit/(loss) for the period	39,516.43	826.70	40,861.10

- 10 The above results includes the results for the quarter ended 31 March 2018, being the balancing figure between audited figures in respect of the full financial year and the recast published year to date figures up to the third quarter of the previous financial year.
- 11 The previous period figures have been regrouped wherever necessary to correspond with the current period disclosure.



For Sequent Scientific Limited

Manish Gupta
Manish Gupta
Managing Director

Place : Mumbai
Date : 09 August 2018

W